Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma

Molecular Therapy

Volumn 18, Issue 3, 2010, Pages 651-659

  Adamina, Michel ^a,b   Rosenthal, Rachel ^a,b   Weber, Walter P ^a,b   Frey, Daniel M ^a,b   Viehl, Carsten T ^a,b   Bolli, Martin ^a,b   Huegli, Rolf W ^a   Jacob, Augustinus L ^a   Heberer, Michael ^a,b   Oertli, Daniel ^a,b   Marti, Walter ^a,b   Spagnoli, Giulio C ^a,b   Zajac, Paul ^a,b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN GP 100; HLA A ANTIGEN; MELAN A; MONOPHENOL MONOOXYGENASE; VACCINIA VACCINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LEUKOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRURITUS; SKIN SURGERY; VIRUS RECOMBINANT; VITILIGO;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; DISEASE PROGRESSION; EPITOPES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNIZATION; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; T-LYMPHOCYTES, CYTOTOXIC; VACCINIA VIRUS;

VACCINIA VIRUS;

EID: 77649270825     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.275     Document Type: Article

References (47)

1. Novellino, L, Castelli, C and Parmiani, G (2005). A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54: 187-207.
2. Gardner, JM, Devoss, JJ, Friedman, RS, Wong, DJ, Tan, YX, Zhou, X et al. (2008). Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321: 843-847.
3. Gotter, J, Brors, B, Hergenhahn, M and Kyewski, B (2004). Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specifc genes colocalized in chromosomal clusters. J Exp Med 199: 155-166.
4. Dutoit, V, Rubio-Godoy, V, Dietrich, PY, Quiqueres, AL, Schnuriger, V, Rimoldi, D et al. (2001). Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specifc cytolytic T lymphocytes show superior antitumor activity. Cancer Res 61: 5850-5856.
5. Schaed, SG, Klimek, VM, Panageas, KS, Musselli, CM, Butterworth, L, Hwu, WJ et al. (2002). T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8: 967-972.
6. Slingluff, CL Jr, Petroni, GR, Yamshchikov, GV, Barnd, DL, Eastham, S, Galavotti, H et al. (2003). Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21: 4016-4026.
7. Speiser, DE, Liénard, D, Rufer, N, Rubio-Godoy, V, Rimoldi, D, Lejeune, F et al. (2005). Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739-746.
8. Amato, RJ, Drury, N, Naylor, S, Jac, J, Saxena, S, Cao, A et al. (2008). Vaccination of prostate cancer patients with modifed vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 31: 577-585.
9. Hofbauer, GF, Baur, T, Bonnet, MC, Tartour, E, Burg, G, Berinstein, NL et al. (2008). Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the infammatory infltrate. Melanoma Res 18: 104-111.
10. Kaufman, HL, Deraffele, G, Mitcham, J, Moroziewicz, D, Cohen, SM, Hurst-Wicker, KS et al. (2005). Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115: 1903-1912.
11. Marshall, JL, Gulley, JL, Arlen, PM, Beetham, PK, Tsang, KY, Slack, R et al. (2005). Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23: 720-731.
12. Oertli, D, Marti, WR, Zajac, P, Noppen, C, Kocher, T, Padovan, E et al. (2002). Rapid induction of specifc cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 13: 569-575.
13. Zajac, P, Oertli, D, Marti, W, Adamina, M, Bolli, M, Guller, U et al. (2003). Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 14: 1497-1510.
14. Bedrosian, I, Mick, R, Xu, S, Nisenbaum, H, Faries, M, Zhang, P et al. (2003). Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21: 3826-3835.
15. Figdor, CG, de Vries, IJ, Lesterhuis, WJ and Melief, CJ (2004). Dendritic cell immunotherapy: mapping the way. Nat Med 10: 475-480.
16. Lesimple, T, Neidhard, EM, Vignard, V, Lefeuvre, C, Adamski, H, Labarrière, N et al. (2006). Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 12: 7380-7388.
17. Nestle, FO, Alijagic, S, Gilliet, M, Sun, Y, Grabbe, S, Dummer, R et al. (1998). Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332.
18. Czerniecki, BJ, Koski, GK, Koldovsky, U, Xu, S, Cohen, PA, Mick, R et al. (2007). Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67: 1842-1852.
19. Hersey, P, Halliday, GM, Farrelly, ML, DeSilva, C, Lett, M and Menzies, SW (2008). Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother 57: 1039-1051.
20. Salcedo, M, Bercovici, N, Taylor, R, Vereecken, P, Massicard, S, Duriau, D et al. (2006). Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55: 819-829.
21. Zajac, P, Oertli, D, Spagnoli, GC, Noppen, C, Schaefer, C, Heberer, M et al. (1997). Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-1/Melan-A 27-35 epitope. Int J Cancer 71: 491-496.
22. Iezzi, G, Protti, M P, Rugarli, C and Bellone, M (1996). B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res 56: 11-15.
23. Lenschow, DJ, Walunas, TL and Bluestone, JA (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol 14: 233-258.
24. Marti, WR, Zajac, P, Spagnoli, G, Heberer, M and Oertli, D (1997). Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro. Cell Immunol 179: 146-152.
25. Tsung, K, Yim, JH, Marti, W, Buller, RM and Norton, JA (1996). Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol 70: 165-171.
26. Schuler-Thurner, B, Dieckmann, D, Keikavoussi, P, Bender, A, Maczek, C, Jonuleit, H et al. (2000). Mage-3 and infuenza-matrix peptide-specifc cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165: 3492-3496.
27. Chianese-Bullock, KA, Irvin, WP Jr, Petroni, GR, Murphy, C, Smolkin, M, Olson, WC et al. (2008). A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 31: 420-430.
28. Meijer, SL, Dols, A, Jensen, SM, Hu, HM, Miller, W, Walker, E et al. (2007). Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother 30: 533-543.
29. Wolchok, JD, Yuan, J, Houghton, AN, Gallardo, HF, Rasalan, TS, Wang, J et al. (2007). Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 15: 2044-2050.
30. Zippelius, A, Batard, P, Rubio-Godoy, V, Bioley, G, Liénard, D, Lejeune, F et al. (2004). Effector function of human tumor-specifc CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 64: 2865-2873.
31. Holmes, JP, Gates, JD, Benavides, LC, Hueman, MT, Carmichael, MG, Patil, R et al. (2008). Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 113: 1666-1675.
32. Gogas, H, Ioannovich, J, Dafni, U, Stavropoulou-Giokas, C, Frangia, K, Tsoutsos, D et al. (2006). Prognostic signifcance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709-718.
33. Palmer, DC, Chan, CC, Gattinoni, L, Wrzesinski, C, Paulos, CM, Hinrichs, CS et al. (2008). Effective tumor treatment targeting a melanoma/melanocyte- associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA 105: 8061-8066.
34. Straatsma, BR, Nusinowitz, S, Young, TA, Gordon, LK, Chun, MW, Rosen, C et al. (2007). Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol 143: 958-969.
35. Shen, Y and Nemunaitis, J (2005). Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 11: 180-195.
36. Arlen, PM, Gulley, JL, Madan, RA, Hodge, JW and Schlom, J (2007). Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 27: 451-462.
37. Smith, CL, Mirza, F, Pasquetto, V, Tscharke, DC, Palmowski, MJ, Dunbar, PR et al. (2005). Immunodominance of poxviral-specifc CTL in a human trial of recombinant-modifed vaccinia Ankara. J Immunol 175: 8431-8437.
38. Zajac, P, Schütz, A, Oertli, D, Noppen, C, Schaefer, C, Heberer, M et al. (1998). Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules. Cancer Res 58: 4567-4571.
39. Speiser, DE, Baumgaertner, P, Voelter, V, Devevre, E, Barbey, C, Rufer, N et al. (2008). Unmodifed self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 105: 3849-3854.
40. Cavazza, A, Adamina, M, Ausiello, CM, Giardina, B, Marini, M, Palazzo, R et al. (2004). Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin Immunol 111: 252-261.
41. Schluns, KS and Lefrançois, L (2003). Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3: 269-279.
42. Schlom, J, Arlen, PM and Gulley, JL (2007). Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 13: 3776-3782.
43. Balch, CM, Buzaid, AC, Soong, SJ, Atkins, MB, Cascinelli, N, Coit, DG et al. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648.
44. Chaux, P, Vantomme, V, Coulie, P, Boon, T and van der Bruggen, P (1998). Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 77: 538-542.
45. Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
46. Shankar, LK, Hoffman, JM, Bacharach, S, Graham, MM, Karp, J, Lammertsma, AA et al.; National Cancer Institute (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47: 1059-1066.
47. Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.